Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell–Engaging Antibody and CD8 T Cells

(2015) Shruthi Prasad et al.   CANCER RESEARCH

Heterodimeric Bispecific Single-Chain Variable-Fragment Antibodies Against EpCAM and CD16 Induce Effective Antibody-Dependent Cellular Cytotoxicity Against Human Carcinoma Cells

(2013) Daniel A. Vallera et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133high cancer stem cells in vitro and in vivo

(2013) Jianhua Huang et al.   CLINICAL IMMUNOLOGY

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression

(2013) Amy P.N. Skubitz et al.   GYNECOLOGIC ONCOLOGY

A dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells

(2013) Ingo Schubert et al.   mAbs

T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 × CD3 or CD19 × CD16

(2012) Lisa M. Pörtner et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production

(2012) M. K. Gleason et al.   MOLECULAR CANCER THERAPEUTICS

Identification and characterization of a novel scFv recognizing human and mouse CD133

(2012) Suresh Kumar Swaminathan et al.   Drug Delivery and Translational Research

Immunotoxin targeting CD133+ breast carcinoma cells

(2012) John R. Ohlfest et al.   Drug Delivery and Translational Research

Construction and humanization of a functional bispecific EGFR × CD16 diabody using a refolding system

(2011) Ryutaro Asano et al.   FEBS Journal

Targeting Tumor-Initiating Cancer Cells with dCD133KDEL Shows Impressive Tumor Reductions in a Xenotransplant Model of Human Head and Neck Cancer

(2011) N. N. Waldron et al.   MOLECULAR CANCER THERAPEUTICS

Innate or Adaptive Immunity? The Example of Natural Killer Cells

(2011) E. Vivier et al.   SCIENCE

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells

(2010) Zhiyong Du et al.   DIGESTIVE DISEASES AND SCIENCES

Identification of a novel monoclonal antibody recognizing CD133

(2010) Suresh Kumar Swaminathan et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Therapeutic implications of colon cancer stem cells

(2010) Eros Fabrizi   WORLD JOURNAL OF GASTROENTEROLOGY

CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers

(2008) L M Smith et al.   BRITISH JOURNAL OF CANCER

Ultrastructural characterization of CD133+stem cells bound to superparamagnetic nanoparticles: possible biotechnological applications

(2008) L. F. PAVON et al.   JOURNAL OF MICROSCOPY